ZelosDx Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Private

  • Employees
  • 7

Employees

  • Latest Deal Type
  • Grant

  • Investors
  • 13

ZelosDx General Information

Description

Developer of neurodiagnostic technologies intended to commercialize blood testing products. The company provides critical data that can be useful in diagnosis, monitoring and assessing therapeutic responses that help to make discoveries for brain health and diseases, enabling pharmaceutical companies and researchers to drug discovery and conduct studies in brain disease.

Contact Information

Website
www.zelosdx.com
Formerly Known As
MSDx
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 245 South Plumer Avenue
  • Suite 7
  • Tucson, AZ 85719
  • United States
+1 (520)
Primary Industry
Discovery Tools (Healthcare)
Vertical(s)
Digital Health, HealthTech, Life Sciences
Corporate Office
  • 245 South Plumer Avenue
  • Suite 7
  • Tucson, AZ 85719
  • United States
+1 (520)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ZelosDx Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Grant 01-Oct-2021 Completed Product In Beta Test
9. Grant 27-Jun-2021 Completed Product Development
8. Later Stage VC 04-May-2021 Completed Product Development
7. Seed Round 01-Jun-2015 Completed Product Development
6. Accelerator/Incubator 03-Oct-2014 Completed Product Development
5. Grant 01-Jan-2013 Completed Product Development
4. Seed Round 27-May-2012 Completed Product Development
3. Grant 01-Jan-2012 Completed Product Development
2. Early Stage VC 03-Dec-2010 $602K $602K Completed Product Development
1. Grant 01-Nov-2010 $205K Completed Product Development
To view ZelosDx’s complete valuation and funding history, request access »

ZelosDx Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A-3
Series A-2
Series A-1 1,200,000 $0.001000 $0.5 $0.5 1x $0.5 10.41%
To view ZelosDx’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

ZelosDx Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of neurodiagnostic technologies intended to commercialize blood testing products. The company provides critica
Discovery Tools (Healthcare)
Tucson, AZ
7 As of 2022

Billerica, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ZelosDx Competitors (1)

One of ZelosDx’s competitors is Quanterix, a Formerly PE-Backed company based in Billerica, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Quanterix Formerly PE-Backed Billerica, MA
You’re viewing 1 of 1 competitors. Get the full list »

ZelosDx Patents

  • 24

    Total Documents Applications and Grants

  • Total Patents Families

  • 14

    Granted

  • 4

    Pending

  • Expiring in next 12 mo

ZelosDx Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220236292-A1 Detection of debris in recirculating phagocytes Pending 09-May-2019
CA-2929711-A1 Detection of neurological diseases via measurement of neuromelanin in recirculating phagocytes Inactive 05-Nov-2012
CA-2900634-A1 Methods for measuring high molecular weight complexes of fibrinogen with fibronectin and fibulin-1 Active 10-Feb-2012
CA-2900634-C Methods for measuring high molecular weight complexes of fibrinogen with fibronectin and fibulin-1 Active 10-Feb-2012
EP-2812696-A1 Methods for measuring high molecular weight complexes of fibrinogen with fibronectin and fibulin-1 Active 10-Feb-2012 G01N33/564
To view ZelosDx’s complete patent history, request access »

ZelosDx Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ZelosDx Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds
U. S. National Science Foundation Government
Hot Ventures Venture Capital Minority
Angel (individual) Minority
Angel (individual) Minority
Angel (individual) Minority
You’re viewing 5 of 13 investors. Get the full list »

Ready to get started?

Request a free trial

ZelosDx FAQs

  • When was ZelosDx founded?

    ZelosDx was founded in 2010.

  • Where is ZelosDx headquartered?

    ZelosDx is headquartered in Tucson, AZ.

  • What is the size of ZelosDx?

    ZelosDx has 7 total employees.

  • What industry is ZelosDx in?

    ZelosDx’s primary industry is Discovery Tools (Healthcare).

  • Is ZelosDx a private or public company?

    ZelosDx is a Private company.

  • What is ZelosDx’s current revenue?

    The current revenue for ZelosDx is .

  • How much funding has ZelosDx raised over time?

    ZelosDx has raised $3.2M.

  • Who are ZelosDx’s investors?

    U. S. National Science Foundation, Hot Ventures, , , and are 5 of 13 investors who have invested in ZelosDx.

  • Who are ZelosDx’s competitors?

    Quanterix is a competitor of ZelosDx.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »